ClinicalTrials.gg
CompletedNCT03921723Updated Jul 31, 2020Results posted

Dolutegravir Pediatric Liquid Formulation Study

A Phase 1 interventional study of Dolutegravir dispersible tablet and Dolutegravir oral suspension in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-31.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Enrollment
48th of 55
22 · median 126
Started
2019
with 7 others
Phase 1
7 of 55
none open now
Registered
35th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 48th largest by enrollment, is one of 8 that started in 2019, is one of 7 in phase 1, and was the 35th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

This is an open-label, single-center, single dose, non-randomized, sequential, fixed-sequence study, which will evaluate pharmacokinetics (PK) of dolutegravir (DTG) in healthy adult subjects. The study will contain 6 periods with five prototype liquid formulations for evaluation in fasted state. In period 1, 2 and 3 single reference dose of 2 dispersible tablets of 5 milligram DTG will be administered and at least 2 liquid prototype DTG formulations (containing a target total dose of 10mg DTG). There will be a wash-out period of 7 days between each period. In period 4 through 6, there would be options to evaluate additional prototype liquid formulations. The total duration of study will be up to 17 weeks. DTG has been found to be safe and effective in adults infected with human immunodeficiency virus (HIV). DTG dispersible tablets have been developed primarily for use in children from 4 weeks to 6 years of age, and a DTG liquid formulation are is being developed to study the appropriate dose needed for the HIV-exposed and infected neonatal population in the first four weeks of life. Approximately 18 subjects will be enrolled in this study.

03

Conditions studied

  • HIV Infections

Keywords

  • Dolutegravir
  • Human immunodeficiency virus
  • Sequential study
  • Dispersible tablet
  • Suspension
  • Liquid solution
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 18 to 55 years of age inclusive, at the time of signing the .
  • Subjects who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac evaluation.
  • Body weight >= 50 kg (110 pounds [lbs]) for men and >=45 kg (99 lbs) for women and (BMI) within the range 18.5-31.0 kilogram per meter square (kg/m\^2) (inclusive).
  • Male and female subjects will be part of study. A female subject is eligible to participate if she is not pregnant or breastfeeding, and is not a woman of (WOCBP).
  • Additional requirements for pregnancy testing, if needed, during and after study intervention; The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Subject should be capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Abnormal blood pressure as determined by the investigator.
  • (ALT) >1.5 times (ULN).
  • >1.5times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • correction using Fridericia Formula (QTcF) >450 millisecond (msec)
  • Past or intended use of over-the-counter or prescription medication (including herbal medications) within 7 days prior to dosing. Paracetamol.
  • History of allergy or sensitivity to DTG.
  • Participation in the study would result in loss of blood or blood products in excess of 500 mL within 56 days.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Current enrollment or past participation within the last 30 days before signing of consent in this or any other clinical study involving an study intervention or any other type of medical research.
  • Presence of surface antigen (HBsAg), or a positive hepatitis B core antibody with a negative hepatitis B surface antibody at screening.
  • Positive antibody test result at screening: Subjects with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C ribonucleic acid (RNA) test is obtained.
  • Positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
  • Positive pre-study drug/alcohol screen.
  • Positive antibody test.
  • Regular use of known drugs of abuse.
  • Regular alcohol consumption within one month prior to the study defined as: For the United Kingdom an average weekly intake of >14 units for males or females. One unit is equivalent to 8 gram (g) of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6 months prior to screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Subject receiving Dolutegravir 10 mg

    Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of \>= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.

    Drug: Dolutegravir dispersible tablet · Drug: Dolutegravir oral suspension · Drug: Dolutegravir oral solution

Interventions

  • DrugDolutegravir dispersible tablet

    DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.

  • DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.

  • DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point (AUC[0-t]) for DTG

    Blood samples were collected at indicated time points and pharmacokinetic (PK) analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

  2. AUC From Time Zero to Infinity (AUC[0-inf]) for DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

  3. Maximum Observed Concentration (Cmax) for DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

Secondary outcomes

  1. Absorption Lag Time (Tlag) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

  2. Time of Maximum Observed Concentration (Tmax) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

  3. Time of Last Quantifiable Concentration (Tlast) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

  4. Elimination Half-life (t½) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

  5. Apparent Elimination Rate Constant (Lambda z) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

  6. Percentage of AUC(0-inf) Extrapolated (%AUCex) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose

  7. AUC From Time Zero to 24 Hours (AUC[0-24]) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, and 24 hours post-dose

  8. AUC From Time Zero to 72 Hours (AUC[0-72]) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  9. Apparent Oral Clearance (CL/F) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  10. Last Quantifiable Concentration (Ct) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  11. Apparent Oral Volume of Distribution (Vz/F) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose

  12. Concentration at 24hours Post-dose (C24) Following Administration of DTG

    Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

    Time frame: 24 hours

  13. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP was measured in a supine position after at least 5 minutes of rest for the participant in a quiet setting without any distractions using a completely automated device. Day -1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specific time point value.

    Time frame: Baseline (Day -1) and Day 4

  14. Change From Baseline in Pulse Rate

    Pulse rate was measured in a supine position after at least 5 minutes of rest for the participant in a quiet setting without any distractions using a completely automated device. Day -1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specific time point value.

    Time frame: Baseline (Day -1) and Day 4

  15. Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose results in death,is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgement.

    Time frame: Up to Week 11

  16. Number of Participants With Clinically Significant Hematology Parameters

    Blood samples were collected to analyze the following hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), percentage reticulocytes and red blood cell count. Data for clinically significant abnormal hematology parameters have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: Baseline (Day -1)

  17. Number of Participants With Clinically Significant Chemistry Parameters

    Blood samples were collected to analyze the following clinical chemistry parameters: Potassium, calcium, sodium, creatinine, glucose, alkaline phosphatase, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Blood urea nitrogen (BUN), total and direct bilirubin, total protein and creatine kinase. Data for clinically significant abnormal clinical chemistry parameters have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: Baseline (Day -1)

  18. Number of Participants With Clinically Significant Urine Parameters

    Urine samples were collected to analyze the following urinalysis parameters: specific gravity, potential of hydrogen (pH). Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: Baseline (Day -1)

07

Results

Posted Jul 31, 2020

Participant flow

This was a Phase 1, open-label, non-randomized, single dose study in healthy adult participants conducted at a single center in the United Kingdom (UK) to assess the prototype liquid fomulations of dolutegravir (DTG) versus DTG dispersible tablets (reference).

Period 1 (4 Days)
Participant flow — Period 1 (4 Days)
MilestonePrototype A/DTG Reference/Prototype B
Started22
Completed22
Not completed0
Period 2 (4 Days)
Participant flow — Period 2 (4 Days)
MilestonePrototype A/DTG Reference/Prototype B
Started22
Completed19
Not completed3
Withdrew: Withdrawal by subject3
Period 3 (4 Days)
Participant flow — Period 3 (4 Days)
MilestonePrototype A/DTG Reference/Prototype B
Started19
Completed18
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryArea Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point (AUC[0-t]) for DTG

Blood samples were collected at indicated time points and pharmacokinetic (PK) analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · Hours*micrograms per milliliter
Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point (AUC[0-t]) for DTG
Hours*micrograms per milliliterPrototype APrototype BDTG Reference
Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point (AUC[0-t]) for DTG11.9968 ± 22.713.7921 ± 20.512.1944 ± 22.7
Statistical analysis
  • Prototype A vs DTG Reference · Ratio: 0.97 · 90% CI 0.91 to 1.03
  • Prototype B vs DTG Reference · Ratio: 1.12 · 90% CI 1.05 to 1.20
SecondaryAbsorption Lag Time (Tlag) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Median · Hours
Absorption Lag Time (Tlag) Following Administration of DTG
HoursPrototype APrototype BDTG Reference
Absorption Lag Time (Tlag) Following Administration of DTG0.0 (0 to 0)0.0 (0 to 0)0.0 (0 to 0)
SecondaryTime of Maximum Observed Concentration (Tmax) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Median · Hours
Time of Maximum Observed Concentration (Tmax) Following Administration of DTG
HoursPrototype APrototype BDTG Reference
Time of Maximum Observed Concentration (Tmax) Following Administration of DTG1.50 (0.5 to 3.5)0.50 (0.5 to 2.0)0.75 (0.5 to 5.0)
SecondaryTime of Last Quantifiable Concentration (Tlast) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Median · Hours
Time of Last Quantifiable Concentration (Tlast) Following Administration of DTG
HoursPrototype APrototype BDTG Reference
Time of Last Quantifiable Concentration (Tlast) Following Administration of DTG48.0000 (47.983 to 72.283)48.0333 (48.000 to 72.317)48.0000 (47.783 to 72.150)
SecondaryElimination Half-life (t½) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · Hours
Elimination Half-life (t½) Following Administration of DTG
HoursPrototype APrototype BDTG Reference
Elimination Half-life (t½) Following Administration of DTG13.6389 ± 17.514.5997 ± 19.113.5807 ± 20.9
SecondaryApparent Elimination Rate Constant (Lambda z) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · Per hour
Apparent Elimination Rate Constant (Lambda z) Following Administration of DTG
Per hourPrototype APrototype BDTG Reference
Apparent Elimination Rate Constant (Lambda z) Following Administration of DTG0.0508 ± 17.50.0475 ± 19.10.0510 ± 20.9
SecondaryPercentage of AUC(0-inf) Extrapolated (%AUCex) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · Percentage of AUCex
Percentage of AUC(0-inf) Extrapolated (%AUCex) Following Administration of DTG
Percentage of AUCexPrototype APrototype BDTG Reference
Percentage of AUC(0-inf) Extrapolated (%AUCex) Following Administration of DTG6.1049 ± 36.85.8582 ± 57.16.3086 ± 36.3
SecondaryAUC From Time Zero to 24 Hours (AUC[0-24]) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, and 24 hours post-dose
Reported as:
Geometric mean · Hours*micrograms per milliliter
AUC From Time Zero to 24 Hours (AUC[0-24]) Following Administration of DTG
Hours*micrograms per milliliterPrototype APrototype BDTG Reference
AUC From Time Zero to 24 Hours (AUC[0-24]) Following Administration of DTG9.2541 ± 16.410.2918 ± 15.89.2356 ± 18.7
SecondaryAUC From Time Zero to 72 Hours (AUC[0-72]) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Hours*micrograms per milliliter
AUC From Time Zero to 72 Hours (AUC[0-72]) Following Administration of DTG
Hours*micrograms per milliliterPrototype APrototype BDTG Reference
AUC From Time Zero to 72 Hours (AUC[0-72]) Following Administration of DTG12.2645 ± 22.014.1062 ± 20.812.5289 ± 21.9
SecondaryApparent Oral Clearance (CL/F) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters per hour
Apparent Oral Clearance (CL/F) Following Administration of DTG
Liters per hourPrototype APrototype BDTG Reference
Apparent Oral Clearance (CL/F) Following Administration of DTG0.7794 ± 23.00.6752 ± 21.80.7650 ± 23.8
SecondaryLast Quantifiable Concentration (Ct) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Last Quantifiable Concentration (Ct) Following Administration of DTG
Micrograms per milliliterPrototype APrototype BDTG Reference
Last Quantifiable Concentration (Ct) Following Administration of DTG0.0398 ± 35.40.0412 ± 53.20.0421 ± 39.9
SecondaryApparent Oral Volume of Distribution (Vz/F) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Reported as:
Geometric mean · Liters
Apparent Oral Volume of Distribution (Vz/F) Following Administration of DTG
LitersPrototype APrototype BDTG Reference
Apparent Oral Volume of Distribution (Vz/F) Following Administration of DTG15.3369 ± 13.814.2222 ± 15.014.9889 ± 19.1
SecondaryConcentration at 24hours Post-dose (C24) Following Administration of DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
24 hours
Reported as:
Geometric mean · Micrograms per milliliter
Concentration at 24hours Post-dose (C24) Following Administration of DTG
Micrograms per milliliterPrototype APrototype BDTG Reference
Concentration at 24hours Post-dose (C24) Following Administration of DTG0.1763 ± 28.50.2167 ± 21.70.1917 ± 22.7
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP was measured in a supine position after at least 5 minutes of rest for the participant in a quiet setting without any distractions using a completely automated device. Day -1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specific time point value.

Time frame:
Baseline (Day -1) and Day 4
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryPrototype APrototype BDTG Reference
SBP, Day 40.3 ± 10.504.9 ± 10.977.3 ± 9.59
DBP, Day 4-0.7 ± 6.831.8 ± 6.077.8 ± 7.05
SecondaryChange From Baseline in Pulse Rate

Pulse rate was measured in a supine position after at least 5 minutes of rest for the participant in a quiet setting without any distractions using a completely automated device. Day -1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specific time point value.

Time frame:
Baseline (Day -1) and Day 4
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate
Beats per minutePrototype APrototype BDTG Reference
Change From Baseline in Pulse Rate6.1 ± 11.066.8 ± 8.544.1 ± 11.38
SecondaryNumber of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose results in death,is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgement.

Time frame:
Up to Week 11
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPrototype APrototype BDTG Reference
Non-serious AEs334
SAEs000
SecondaryNumber of Participants With Clinically Significant Hematology Parameters

Blood samples were collected to analyze the following hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), percentage reticulocytes and red blood cell count. Data for clinically significant abnormal hematology parameters have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
Baseline (Day -1)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Hematology Parameters
ParticipantsPrototype APrototype BDTG Reference
Number of Participants With Clinically Significant Hematology Parameters000
SecondaryNumber of Participants With Clinically Significant Chemistry Parameters

Blood samples were collected to analyze the following clinical chemistry parameters: Potassium, calcium, sodium, creatinine, glucose, alkaline phosphatase, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Blood urea nitrogen (BUN), total and direct bilirubin, total protein and creatine kinase. Data for clinically significant abnormal clinical chemistry parameters have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
Baseline (Day -1)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Chemistry Parameters
ParticipantsPrototype APrototype BDTG Reference
Number of Participants With Clinically Significant Chemistry Parameters000
SecondaryNumber of Participants With Clinically Significant Urine Parameters

Urine samples were collected to analyze the following urinalysis parameters: specific gravity, potential of hydrogen (pH). Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
Baseline (Day -1)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Urine Parameters
ParticipantsPrototype APrototype BDTG Reference
Number of Participants With Clinically Significant Urine Parameters000
PrimaryAUC From Time Zero to Infinity (AUC[0-inf]) for DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · Hours*micrograms per milliliter
AUC From Time Zero to Infinity (AUC[0-inf]) for DTG
Hours*micrograms per milliliterPrototype APrototype BDTG Reference
AUC From Time Zero to Infinity (AUC[0-inf]) for DTG12.8297 ± 23.014.8099 ± 21.813.0715 ± 23.8
Statistical analysis
  • Prototype A vs DTG Reference · Ratio: 0.96 · 90% CI 0.91 to 1.03
  • Prototype B vs DTG Reference · Ratio: 1.13 · 90% CI 1.06 to 1.20
PrimaryMaximum Observed Concentration (Cmax) for DTG

Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Observed Concentration (Cmax) for DTG
Micrograms per milliliterPrototype APrototype BDTG Reference
Maximum Observed Concentration (Cmax) for DTG0.9200 ± 14.40.9993 ± 17.60.8200 ± 26.1
Statistical analysis
  • Prototype A vs DTG Reference · Ratio: 1.09 · 90% CI 1.01 to 1.19
  • Prototype B vs DTG Reference · Ratio: 1.22 · 90% CI 1.13 to 1.33

Adverse events

Collected over Non-serious and serious adverse events were collected up to Week 11. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prototype A0/18 (0%)0/18 (0%)3/18 (16.7%)
Prototype B0/19 (0%)0/19 (0%)3/19 (15.8%)
DTG Reference0/22 (0%)0/22 (0%)4/22 (18.2%)
Most frequent other events
Most frequent other events
EventPrototype APrototype BDTG Reference
HeadacheNervous system disorders0/181/192/22
Tension headacheNervous system disorders1/180/190/22
DiarrhoeaGastrointestinal disorders1/180/190/22
EpistaxisRespiratory, thoracic and mediastinal disorders1/180/190/22
Arthropod biteInjury, poisoning and procedural complications0/181/190/22
Skin abrasionInjury, poisoning and procedural complications0/181/190/22
Nasal congestionRespiratory, thoracic and mediastinal disorders0/181/190/22
HordeolumInfections and infestations0/180/191/22
Rash erythematousSkin and subcutaneous tissue disorders0/180/191/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Prototype A/DTG Reference/Prototype B
Mean31.3 ± 7.93
Sex: Female, Male
Sex: Female, Male(Participants)Prototype A/DTG Reference/Prototype B
Female0
Male22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Prototype A/DTG Reference/Prototype B
CENTRAL/SOUTH ASIAN HERITAGE1
BLACK OR AFRICAN AMERICAN2
WHITE/CAUCASIAN/EUROPEAN HERITAGE19
08

Study locations

1 site
  • GSK Investigational Site
    Nottingham, NG11 6JS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jul 2019, 2 months.

Results were first posted in Jul 2020, 1 year after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 2 months is below that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 19, 2019
StartActual
May 7, 2019
Primary completionActual
Jul 25, 2019
CompletionActual
Jul 25, 2019
Results first posted
Jul 31, 2020
Last update
Jul 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03921723
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Apr 19, 2019
Start date
May 7, 2019
Primary completion
Jul 25, 2019
Completion
Jul 25, 2019
Results posted
Jul 31, 2020
Last update
Jul 31, 2020

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion